DSIJ Mindshare

Natco Pharma shines on getting nod from CDSCO for emergency use of Baricitinib tablets

Apurva Joshi 1 1016 Article rating: 5.0

Natco Pharma Limited has informed the bourses that it has received emergency use approval for Baricitinib tablets in strengths of 1 mg, 2 mg, and 4 mg from Central Drugs Standard Control Organisation (CDSCO), India. Baricitinib, combined with Remdesivir, is used for the treatment of COVID-19 positive patients.

Corinth Group of Switzerland to invest USD 100 million in Morepen Laboratories

Apurva Joshi 0 1340 Article rating: 4.7

The board of directors of Morepen Laboratories Limited has approved the investment proposed by Corinth Group, a global private investment group, headquartered in Switzerland, to the extent of USD 32.50 million in the parent company, Morepen Laboratories Limited out of a total USD 100 million investment in the promoter group. 

RSS
First678911131415Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR